Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Onkologia w Praktyce Klinicznej - Edukacja
MENU
Na skróty Ahead of print Zdeponuj artykuł Nagroda imienia Profesora Krzysztofa Krzemienieckiego Zalecenia postępowania diagnostyczno-terapeutycznego

dostęp otwarty

Tom 8, Nr 4 (2022)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2022-03-03
Pokaż PDF Pokaż HTML
Pobierz cytowanie

Zalecenia postępowania diagnostyczno-terapeutycznego w raku pęcherza moczowego

Piotr J. Wysocki1, Piotr Chłosta2, Artur Antoniewicz3, Robert Chrzan4, Anna K. Czech2, Przemysław Dudek5, Katarzyna Gronostaj2, Maciej Krzakowski6, Łukasz Kwinta1, Jakub Kucharz7, Krzysztof Małecki8, Krzysztof Okoń910, Mikołaj Przydacz2, Iwona Skoneczna1112, Paweł Wiechno7
Onkol Prakt Klin Edu 2022;8(4):229-291.
Afiliacje
  1. Katedra i Klinika Onkologii, Uniwersytet Jagielloński — Collegium Medicum w Krakowie
  2. Katedra i Klinika Urologii, Uniwersytet Jagielloński — Collegium Medicum w Krakowie
  3. Międzyleski Szpital Specjalistyczny w Warszawie
  4. Katedra Radiologii, Uniwersytet Jagielloński — Collegium Medicum w Krakowie
  5. Oddział Kliniczny Urologii i Urologii Onkologicznej, Szpital Uniwersytecki w Krakowie
  6. Klinika Nowotworów Płuca i Klatki Piersiowej, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie
  7. Klinika Nowotworów Układu Moczowego, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie
  8. Zakład Radioterapii Dzieci i Dorosłych, Uniwersytecki Szpital Dziecięcy w Krakowie
  9. Katedra Patomorfologii, Uniwersytet Jagielloński — Collegium Medicum w Krakowie
  10. Zakład Diagnostyki Patomorfologicznej Szpitala Uniwersyteckiego w Krakowie
  11. Szpital Grochowski im. dr med. Rafała Masztaka w Warszawie
  12. Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie

dostęp otwarty

Tom 8, Nr 4 (2022)
WYTYCZNE POSTĘPOWANIA DIAGNOSTYCZNO-TERAPEUTYCZNEGO
Opublikowany online: 2022-03-03

Streszczenie

Brak

Streszczenie

Brak

Pełny tekst:

Pokaż PDF Pokaż HTML
Pobierz cytowanie

Słowa kluczowe

rak pęcherza moczowego; rak urotelialny; rak przejściowo komórkowy; rak cewki moczowej; rak moczowodu; rak miedniczki nerkowej

Informacje o artykule
Tytuł

Zalecenia postępowania diagnostyczno-terapeutycznego w raku pęcherza moczowego

Czasopismo

Onkologia w Praktyce Klinicznej - Edukacja

Numer

Tom 8, Nr 4 (2022)

Typ artykułu

Wytyczne / stanowisko ekspertów

Strony

229-291

Opublikowany online

2022-03-03

Wyświetlenia strony

2649

Wyświetlenia/pobrania artykułu

4883

Rekord bibliograficzny

Onkol Prakt Klin Edu 2022;8(4):229-291.

Słowa kluczowe

rak pęcherza moczowego
rak urotelialny
rak przejściowo komórkowy
rak cewki moczowej
rak moczowodu
rak miedniczki nerkowej

Autorzy

Piotr J. Wysocki
Piotr Chłosta
Artur Antoniewicz
Robert Chrzan
Anna K. Czech
Przemysław Dudek
Katarzyna Gronostaj
Maciej Krzakowski
Łukasz Kwinta
Jakub Kucharz
Krzysztof Małecki
Krzysztof Okoń
Mikołaj Przydacz
Iwona Skoneczna
Paweł Wiechno

Referencje (403)
  1. Montori VM, Guyatt GH. Progress in evidence-based medicine. JAMA. 2008; 300(15): 1814–1816.
    CrossRefPubMed
  2. Cherny NI, Dafni U, Bogaerts J, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017; 28(10): 2340–2366.
    CrossRefPubMed
  3. Krzakowski M, Wysocki P, Jassem J, et al. Algorytm oceny wartości nowych leków przeciwnowotworowych — propozycje Polskiego Towarzystwa Onkologii Klinicznej i Polskiego Towarzystwa Onkologicznego. Onkol Prak Klin. 2015; 11(1): 9–15.
  4. Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of Bladder Cancer. Med Sci (Basel). 2020; 8(1).
    CrossRefPubMed
  5. http://onkologia.org.pl. (24.05.2021).
  6. https://gco.iarc.fr. (24.05.2021).
  7. https://seer.cancer.gov. (24.05.2021).
  8. Felix AS, Soliman AS, Khaled H, et al. The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control. 2008; 19(4): 421–429.
    CrossRefPubMed
  9. Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol. 2003; 44(6): 672–681.
    CrossRef
  10. Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011; 306(7): 737–745.
    CrossRefPubMed
  11. Cumberbatch MG, Rota M, Catto JWF, et al. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol. 2016; 70(3): 458–466.
    CrossRefPubMed
  12. Jiang X, Yuan JM, Skipper PL, et al. Environmental tobacco smoke and bladder cancer risk in never smokers of Los Angeles County. Cancer Res. 2007; 67(15): 7540–7545.
    CrossRefPubMed
  13. Cacciamani GE, Ghodoussipour S, Mari A, et al. Association between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes following Radical Cystectomy: Systematic Review and Meta-Analysis. J Urol. 2020; 204(4): 649–660.
    CrossRefPubMed
  14. Kogevinas M, Mannetje A, Cordier S, et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes & Control. 2003; 14(10): 907–914.
    CrossRef
  15. Colt JS, Karagas MR, Schwenn M, et al. Occupation and bladder cancer in a population-based case-control study in Northern New England. Occup Environ Med. 2011; 68(4): 239–249.
    CrossRefPubMed
  16. Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1995; 87(7): 524–531.
    CrossRef
  17. Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med. 1985; 313(5): 292–295.
    CrossRefPubMed
  18. Liang Z, Wang X, Xie Bo, et al. Pesticide exposure and risk of bladder cancer: A meta-analysis. Oncotarget. 2016; 7(41): 66959–66969.
    CrossRefPubMed
  19. Chung CJ, Huang YL, Huang YK, et al. Urinary arsenic profiles and the risks of cancer mortality: a population-based 20-year follow-up study in arseniasis-endemic areas in Taiwan. Environ Res. 2013; 122: 25–30.
    CrossRefPubMed
  20. Villanueva CM, Fernández F, Malats N, et al. Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J Epidemiol Community Health. 2003; 57(3): 166–173.
    CrossRefPubMed
  21. García-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. The Lancet. 2005; 366(9486): 649–659.
    CrossRefPubMed
  22. Park SY, Ollberding NJ, Woolcott CG, et al. Fruit and vegetable intakes are associated with lower risk of bladder cancer among women in the Multiethnic Cohort Study. J Nutr. 2013; 143(8): 1283–1292.
    CrossRefPubMed
  23. Larsson SC, Andersson SO, Johansson JE, et al. Fruit and vegetable consumption and risk of bladder cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2008; 17(9): 2519–2522.
    CrossRefPubMed
  24. Pesch B, Nasterlack M, Eberle F, et al. UroScreen Group. The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU Int. 2011; 108(4): 546–552.
    CrossRefPubMed
  25. Chou R, Gore JL, Buckley D, et al. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis. Ann Intern Med. 2015; 163(12): 922–931.
    CrossRefPubMed
  26. Khadra MH, Pickard RS, Charlton M, et al. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000; 163(2): 524–527.
    PubMed
  27. Pall M, Iqbal J, Singh SK, et al. CA 19-9 as a serum marker in urothelial carcinoma. Urol Ann. 2012; 4(2): 98–101.
    CrossRefPubMed
  28. Hegele A, Mecklenburg V, Varga Z, et al. CA19.9 and CEA in transitional cell carcinoma of the bladder: serological and immunohistochemical findings. Anticancer Res. 2010; 30(12): 5195–5200.
    PubMed
  29. Manvar AM, Wallen EM, Pruthi RS, et al. Prognostic value of CA 125 in transitional cell carcinoma of the bladder. Expert Rev Anticancer Ther. 2010; 10(12): 1877–1881.
    CrossRefPubMed
  30. Andreadis C, Touloupidis S, Galaktidou G, et al. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. J Urol. 2005; 174(5): 1771–5; discussion 1775.
    CrossRefPubMed
  31. Wu M, Lin P, Xu L, et al. Prognostic Role of Serum Lactate Dehydrogenase in Patients With Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol. 2020; 10: 677.
    CrossRefPubMed
  32. Tekes A, Kamel IR, Imam K, et al. MR imaging features of transitional cell carcinoma of the urinary bladder. AJR Am J Roentgenol. 2003; 180(3): 771–777.
    CrossRefPubMed
  33. Takeuchi M, Sasaki S, Ito M, et al. Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology. 2009; 251(1): 112–121.
    CrossRefPubMed
  34. Takahashi N, Glockner JF, Hartman RP, et al. Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J Urol. 2010; 183(4): 1330–1365.
    CrossRefPubMed
  35. Thomsen HS. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am. 2009; 47(5): 827–31, vi.
    CrossRefPubMed
  36. Trinh TW, Glazer DI, Sadow CA, et al. Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results. Abdom Radiol (NY). 2018; 43(3): 663–671.
    CrossRefPubMed
  37. Paik ML, Scolieri MJ, Brown SL, et al. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000; 163(6): 1693–1696.
    PubMed
  38. Kundra V, Silverman PM. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. AJR Am J Roentgenol. 2003; 180(4): 1045–1054.
    CrossRefPubMed
  39. Sadow CA, Silverman SG, O'Leary MP, et al. Bladder cancer detection with CT urography in an Academic Medical Center. Radiology. 2008; 249(1): 195–202.
    CrossRefPubMed
  40. Palou J, Rodríguez-Rubio F, Huguet J, et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol. 2005; 174(3): 859–61; discussion 861.
    CrossRefPubMed
  41. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol. 2000; 164(4): 1183–1187.
    PubMed
  42. Picchio M, Treiber U, Beer AJ, et al. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med. 2006; 47(6): 938–944.
    PubMed
  43. Vind-Kezunovic S, Bouchelouche K, Ipsen P, et al. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Results from a High-volume Centre Including Long-term Follow-up. Eur Urol Focus. 2019; 5(1): 90–96.
    CrossRefPubMed
  44. Hałoń A, Okoń K. Rak pęcherza moczowego. In: Nasierowska-Guttmejer A, Górnicka B. ed. Zalecenia do diagnostyki histopatologicznej nowotworów. Centrum Onkologii, Oddział Gliwice, Polskie Towarzystwo Patologów, Gliwice 2013.
  45. Okoń K, Hałoń A. Układ moczowo-płciowy. W: standardy oceny makroskopowej materiału biopsyjnego i operacyjnego u chorych na nowotwory złośliwe. Pol J Pathol. 2015; 66(4): S56–64. 46.
  46. Langfort R, Marszałek A, Ryś J (ed). Patomorfologia: standardy i przykłady dobrej praktyki oraz elementy diagnostyki różnicowej Wytyczne dla pracowni/zakładów patomorfologii. http://pol-pat.pl/index.php/standardy-i-wytyczne-w-patomorfologii/.
  47. Langfort R, Marszałek A, Ryś J (ed). Standardy organizacyjne oraz standardy postępowania w patomorfologii. Wytyczne dla pracowni/zakładów patomorfologii. http://pol-pat.pl/index.php/standardy-i-wytyczne-w-patomorfologii/.
  48. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998; 22(12): 1435–1448.
    CrossRefPubMed
  49. Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016; 70(1): 106–119.
    CrossRefPubMed
  50. Wang G, McKenney JK. Urinary Bladder Pathology: World Health Organization Classification and American Joint Committee on Cancer Staging Update. Arch Pathol Lab Med. 2019; 143(5): 571–577.
    CrossRefPubMed
  51. Bohner BH, Hansel DE, Efstahiou JA. Urinary bladder. In: Amin RB, Efstahiou JA. ed. AJCC cancer staging manual, 8th edition. American Joint Committee on Cancer. Springer 2017.
  52. Kompleksowa opieka onkologiczna – model organizacji diagnostyki i leczenia nowotworu złośliwego pęcherza moczowego; Agencja Oceny Technologii Medycznych i Taryfikacji Wydział Świadczeń Opieki Zdrowotnej; Opracowanie analityczne AOTMiTNr: WS.4320.6.2020. https://bipold.aotm.gov.pl/ assets/files/zlecenia_mz/ 2018/089/RPT/WS.4320.6.2020_RAPORT_RPM_BIP.pdf.
  53. EAU Guidelines Non-muscle-invasive Bladder Cancer NMIBC 2021. https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/#7.
  54. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Joint Guideline (2020). https://www.auanet.org/guidelines/guidelines/bladder-cancer-non-muscle-invasive-guideline.
  55. Chang SS, Boorjian SA, Chou R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016; 196(4): 1021–1029.
    CrossRefPubMed
  56. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bladder Cancer Version 3.2021. https://www.nccn.org/professionals/ physician_gls/pdf/bladder.pdf (22.04.2021).
  57. NOWOTWÓR PĘCHERZA MOCZOWEGO Rekomendacje w zakresie kompleksowej opieki nad pacjentem; PTU 2018. https://www.pturol. org.pl/Image/files/Raport nowotwór%20 pęcherza moczowego.pdf.
  58. Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3): 466–5; discussion 475.
    CrossRefPubMed
  59. Lammers RJM, Hendriks JCM, Rodriguez Faba OR, et al. Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation. World J Urol. 2016; 34(2): 173–180.
    CrossRefPubMed
  60. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009; 182(5): 2195–2203.
    CrossRef
  61. van Rhijn BWG, Zuiverloon TCM, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010; 58(3): 433–441.
    CrossRefPubMed
  62. Fernandez-Gomez J, Madero R, Solsona E, et al. Club Urológico Español de Tratamiento Oncológico. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol. 2011; 60(3): 423–430.
    CrossRefPubMed
  63. Cambier S, Sylvester RJ, Collette L, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol. 2016; 69(1): 60–69.
    CrossRefPubMed
  64. Jobczyk M, et al. Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non–muscle-invasive Bladder Cancer. Eur Urol Oncol (2021), https://doi.org/10.1016/j. euo.2021.05.006.
  65. Sylvester RJ, Rodríguez O, Hernández V, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021; 79(4): 480–488.
    CrossRef
  66. Palou J, Sylvester RJ, Faba OR, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol. 2012; 62(1): 118–125.
    CrossRefPubMed
  67. Gontero P, Sylvester R, Pisano F, et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol. 2015; 67(1): 74–82.
    CrossRef
  68. Dalbagni G, Vora K, Kaag M, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol. 2009; 56(6): 903–910.
    CrossRef
  69. Bishr M, Lattouf JB, Latour M, et al. Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Can Urol Assoc J. 2014; 8(5-6): E306–E310.
    CrossRefPubMed
  70. Palou J, Pisano F, Sylvester R, et al. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. World J Urol. 2018; 36(10): 1621–1627.
    CrossRefPubMed
  71. Palou J, Rodríguez-Rubio F, Millán F, et al. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. Urology. 2009; 73(6): 1313–1317.
    CrossRefPubMed
  72. Alkhateeb SS, Neill M, Bar-Moshe S, et al. Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. Urol Ann. 2011; 3(3): 119–126.
    CrossRefPubMed
  73. Lamm DL. Carcinoma in situ. Urol Clin North Am. 1992; 19: 499.
  74. Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol. 2000; 163(1): 68–71; discussion 71.
    PubMed
  75. Lammers RJ, et al. Smoking status is a risk factor for recurrence after transurethral resect ion of non-muscle-invasive bladder cancer. Eur Urol. 2011; 60(713): 199.
  76. Rink M, Xylinas E, Babjuk M, et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol. 2012; 188(6): 2120–2127.
    CrossRefPubMed
  77. Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002; 41(5): 523–531.
    CrossRef
  78. Oosterlinck W, Kurth KH, Schröder F, et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993; 149(4): 749–752.
    CrossRefPubMed
  79. Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol. 2016; 69: 231.
  80. Perlis N, Zlotta AR, Beyene J, et al. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol. 2013; 64(3): 421–430.
    CrossRefPubMed
  81. Messing EM, Tangen CM, Lerner SP, et al. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018; 319: 1880.
  82. Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996; 155: 1233.
  83. Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 2001; 21: 765.
  84. Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004; 63(4): 682–6; discussion 686.
    CrossRefPubMed
  85. SYLVESTER R, MEIJDEN Av, LAMM D. Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer:. J Urol. 2002: 1964–1970.
    CrossRef
  86. Au JL, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001; 93: 597.
  87. Malmström PU, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56: 247.
  88. Han RFa, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006; 67(6): 1216–1223.
    CrossRefPubMed
  89. Boehm BE, Cornell JE, Wang H, et al. Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis. J Urol. 2017; 198(3): 503–510.
    CrossRefPubMed
  90. Larsen ES, Nordholm AC, Lillebaek T, et al. The epidemiology of bacille Calmette-Guérin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int. 2019; 124(6): 910–916.
    CrossRefPubMed
  91. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976; 116(2): 180–183.
    CrossRefPubMed
  92. Grimm MO, van der Heijden AG, Colombel M, et al. Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS”. Eur Urol. 2020; 78(5): 690–698.
    CrossRefPubMed
  93. Martínez-Piñeiro L, Portillo JA, Fernández JM, et al. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. Eur Urol. 2015; 68(2): 256–262.
    CrossRefPubMed
  94. Oddens J, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013; 63: 462.
  95. Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, et al. Club Urológico Español de Tratamiento Oncológico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol. 2005; 174(4 Pt 1): 1242–1247.
    CrossRefPubMed
  96. Ojea A, Nogueira JL, Solsona E, et al. CUETO Group (Club Urológico Español De Tratamiento Oncológico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol. 2007; 52(5): 1398–1406.
    CrossRefPubMed
  97. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009; 115(6): 1224–1233.
    CrossRefPubMed
  98. Hafeez S, Warren-Oseni K, McNair HA, et al. Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2016; 94(5): 1022–1030.
    CrossRefPubMed
  99. U.S. Food and Drug Administration (FDA). BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry. Center for Drug Evaluation and Research. 2018 [access date March 2021].
  100. Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. Eur Urol. 2019; 75(1): 63–71.
    CrossRefPubMed
  101. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006; 176(6 Pt 1): 2414–22; discussion 2422.
    CrossRefPubMed
  102. Herr HW, et al. Management of low grade papillary bladder tumors. J Urol. 2007; 178.
  103. Hernández V, Llorente C, de la Peña E, et al. Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer. Urol Oncol. 2016; 34(4): 165.e19–165.e23.
    CrossRefPubMed
  104. Hurle R, Lazzeri M, Vanni E, et al. Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project. J Urol. 2018; 199(2): 401–406.
    CrossRefPubMed
  105. Soukup V, Babjuk M, Bellmunt J, et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol. 2012; 62(2): 290–302.
    CrossRefPubMed
  106. Holmäng S, Ströck V. Should follow-up cystoscopy in bacillus Calmette-Guérin-treated patients continue after five tumour-free years? Eur Urol. 2012; 61(3): 503–507.
    CrossRefPubMed
  107. Witjes A, Bruins HM, Cathomas R, et al. Guidelines on Muscle-invasive and Metastatic Bladder CancerEdn. presented at the EAU Annual Congress Milan 2021. EAU Guidelines Office, Arnhem.
  108. Dutta R, Abdelhalim A, Martin JW, et al. Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. Urol Oncol. 2016; 34(12): 531.e1–531.e6.
    CrossRefPubMed
  109. Mathieu R, Lucca I, Rouprêt M, et al. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol. 2016; 13(8): 471–470.
    CrossRef
  110. Kimura S, Mari A, Foerster B, et al. Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis. J Urol. 2019; 201(1): 46–53.
    CrossRefPubMed
  111. Svatek RS, Clinton TN, Wilson CA, et al. Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. Urology. 2014; 84(5): 1147–1151.
    CrossRefPubMed
  112. Moschini M, Soria F, Susani M, et al. Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. Bladder Cancer. 2017; 3(3): 161–169.
    CrossRefPubMed
  113. Ojerholm E, Smith A, Hwang WT, et al. Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer. 2017; 123(5): 794–801.
    CrossRefPubMed
  114. Ku JaH, Kang M, Kim HS, et al. Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis. BMC Cancer. 2015; 15: 447.
    CrossRefPubMed
  115. Jensen JB, Ulhøi BP, Jensen KME. Evaluation of different lymph node (LN) variables as prognostic markers in patients undergoing radical cystectomy and extended LN dissection to the level of the inferior mesenteric artery. BJU Int. 2012; 109(3): 388–393.
    CrossRefPubMed
  116. Fosså SD, Ous S, Berner A. Clinical significance of the „palpable mass” in patients with muscle-infiltrating bladder cancer undergoing cystectomy after pre-operative radiotherapy. Br J Urol. 1991; 67(1): 54–60.
    CrossRefPubMed
  117. Ploeg M, Kiemeney LA, Smits GA, et al. Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. Urol Oncol. 2012; 30(3): 247–251.
    CrossRefPubMed
  118. Knox MK, Cowan NC, Rivers-Bowerman MD, et al. Evaluation of multidetector computed tomography urography and ultrasonography for diagnosing bladder cancer. Clin Radiol. 2008; 63(12): 1317–1325.
    CrossRefPubMed
  119. Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005; 66(6 Suppl 1): 35–63.
    CrossRefPubMed
  120. Barkan GA, Wojcik EM, Nayar R, et al. The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology. Adv Anat Pathol. 2016; 23(4): 193–201.
    CrossRef
  121. Mariappan P, Zachou A, Grigor KM, et al. Edinburgh Uro-Oncology Group. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol. 2010; 57(5): 843–849.
    CrossRefPubMed
  122. Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013; 64(5): 846–854.
    CrossRefPubMed
  123. Weiner AB, Desai AS, Meeks JJ. Tumor Location May Predict Adverse Pathology and Survival Following Definitive Treatment for Bladder Cancer: A National Cohort Study. Eur Urol Oncol. 2019; 2(3): 304–310.
    CrossRefPubMed
  124. Mungan MU, Canda AE, Tuzel E, et al. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. Eur Urol. 2005; 48(5): 760–763.
    CrossRefPubMed
  125. Kassouf W, Spiess PE, Brown GA, et al. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. J Urol. 2008; 180(1): 164–7; discussion 167.
    CrossRefPubMed
  126. Kates M, Ball MW, Chappidi MR, et al. Accuracy of urethral frozen section during radical cystectomy for bladder cancer. Urol Oncol. 2016; 34(12): 532.e1–532.e6.
    CrossRefPubMed
  127. Damiano R, Di Lorenzo G, Cantiello F, et al. Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. Eur Urol. 2007; 52(3): 648–657.
    CrossRefPubMed
  128. Bruins HM, Djaladat H, Ahmadi H, et al. Incidental prostate cancer in patients with bladder urothelial carcinoma: comprehensive analysis of 1,476 radical cystoprostatectomy specimens. J Urol. 2013; 190(5): 1704–1709.
    CrossRefPubMed
  129. Hautmann RE, Abol-Enein H, Hafez K, et al. Urinary diversion. Urology. 2007; 69: 17–49.
    CrossRef
  130. Vordos D, Hoznek A, Gettman M, et al. Laparoscopic Cystectomy – Evolution of A New Technique. EAU Update Series. 2005; 3(3): 147–155.
    CrossRef
  131. Haber GP, Campbell SC, Colombo JR, et al. Perioperative outcomes with laparoscopic radical cystectomy: „pure laparoscopic” and „open-assisted laparoscopic” approaches. Urology. 2007; 70(5): 910–915.
    CrossRefPubMed
  132. Chłosta P, Drewa T, Olejniczak P, et al. Laparoscopic radical cystectomy: operative and pathologic outcomes. Post N Med. 2012; 25: 320–324.
  133. Schumacher MC, Jonsson MN, Wiklund NP. Does extended lymphadenectomy preclude laparoscopic or robot-assisted radical cystectomy in advanced bladder cancer? Curr Opin Urol. 2009; 19(5): 527–532.
    CrossRefPubMed
  134. Kasraeian A, Barret E, Cathelineau X, et al. Robot-assisted laparoscopic cystoprostatectomy with extended pelvic lymphadenectomy, extracorporeal enterocystoplasty, and intracorporeal enterourethral anastomosis: initial Montsouris experience. J Endourol. 2010; 24(3): 409–413.
    CrossRefPubMed
  135. Ng CK, Kauffman EC, Lee MM, et al. A comparison of postoperative complications in open versus robotic cystectomy. Eur Urol. 2010; 57(2): 274–281.
    CrossRefPubMed
  136. Pruthi RS, Nix J, McRackan D, et al. Robotic-assisted laparoscopic intracorporeal urinary diversion. Eur Urol. 2010; 57(6): 1013–1021.
    CrossRefPubMed
  137. Chade DC, Laudone VP, Bochner BH, et al. Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approaches. J Urol. 2010; 183(3): 862–869.
    CrossRefPubMed
  138. Rödel C, Grabenbauer GG, Kühn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20(14): 3061–3071.
    CrossRefPubMed
  139. Caffo O, Fellin G, Graffer U, et al. Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies. Cancer. 2011; 117(6): 1190–1196.
    CrossRefPubMed
  140. Krause FS, Walter B, Ott OJ, et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res. 2011; 31(3): 985–990.
    PubMed
  141. MILLER D, TAUB D, DUNN R, et al. The Impact Of Co-morbid Disease on Cancer Control and Survival Following Radical Cystectomy. The Journal of Urology. 2003: 105–109.
    CrossRef
  142. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998; 16(4): 1582–1587.
    CrossRefPubMed
  143. Gore JL, Lai J, Setodji CM, et al. Urologic Diseases in America Project. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer. 2009; 115(5): 988–996.
    CrossRefPubMed
  144. Russell B, Liedberg F, Khan MS, et al. A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer Patients. Eur Urol Oncol. 2020; 3(2): 239.
  145. Stenzl A, Nagele U, Kuczyk M, et al. Cystectomy – Technical Considerations in Male and Female Patients. EAU Update Series. 2005; 3(3): 138–146.
    CrossRef
  146. Hernández V, Espinos EL, Dunn J, et al. Oncological and functional outcomes of sexual function-preserving cystectomy compared with standard radical cystectomy in men: A systematic review. Urol Oncol. 2017; 35(9): 539.e17–539.e29.
    CrossRefPubMed
  147. Veskimäe E, Neuzillet Y, Rouanne M, et al. Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. BJU Int. 2017; 120(1): 12–24.
    CrossRefPubMed
  148. Gotsadze DT. Why and how to modify standard cystectomy. Urologiia. 2008: 22.
  149. Rozet F, Lesur G, Cathelineau X, et al. Oncological evaluation of prostate sparing cystectomy: the Montsouris long-term results. J Urol. 2008; 179(6): 2170–4; discussion 2174.
    CrossRefPubMed
  150. Muto G, Collura D, Rosso R, et al. Seminal-sparing cystectomy: technical evolution and results over a 20-year period. Urology. 2014; 83(4): 856–861.
    CrossRefPubMed
  151. Pruthi RS, Nielsen M, Smith A, et al. Fast track program in patients undergoing radical cystectomy: results in 362 consecutive patients. J Am Coll Surg. 2010; 210(1): 93–99.
    CrossRefPubMed
  152. Maffezzini M, Campodonico F, Canepa G, et al. Current perioperative management of radical cystectomy with intestinal urinary reconstruction for muscle-invasive bladder cancer and reduction of the incidence of postoperative ileus. Surg Oncol. 2008; 17(1): 41–48.
    CrossRefPubMed
  153. Voigt M, Hemal K, Matthews C. Influence of Simple and Radical Cystectomy on Sexual Function and Pelvic Organ Prolapse in Female Patients: A Scoping Review of the Literature. Sex Med Rev. 2019; 7(3): 408–415.
    CrossRefPubMed
  154. Ali-El-Dein B, Mosbah A, Osman Y, et al. Preservation of the internal genital organs during radical cystectomy in selected women with bladder cancer: a report on 15 cases with long term follow-up. Eur J Surg Oncol. 2013; 39(4): 358–364.
    CrossRefPubMed
  155. Ali-El-Dein B, Abdel-Latif M, Mosbah A, et al. Secondary malignant involvement of gynecologic organs in radical cystectomy specimens in women: is it mandatory to remove these organs routinely? J Urol. 2004; 172(3): 885–887.
    CrossRefPubMed
  156. Temkin SM, Bergstrom J, Samimi G, et al. Ovarian Cancer Prevention in High-risk Women. Clin Obstet Gynecol. 2017; 60(4): 738–757.
    CrossRefPubMed
  157. Bai S, Yao Z, Zhu X, et al. The Feasibility and Safety of Reproductive Organ Preserving Radical Cystectomy for Elderly Female Patients With Muscle-Invasive Bladder Cancer: A Retrospective Propensity Score-matched Study. Urology. 2019; 125: 138–145.
    CrossRefPubMed
  158. Stenzl A, Ninkovic M, Strasser H, et al. Bladder substitution. Curr Opin Urol. 1999; 9(3): 241–245.
    CrossRefPubMed
  159. Yang LS, Shan BL, Shan LL, et al. A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. Surg Oncol. 2016; 25(3): 281–297.
    CrossRefPubMed
  160. Roth B, Furrer MA, Giannakis I, et al. Positive Pre-cystectomy Biopsies of the Prostatic Urethra or Bladder Neck Do Not Necessarily Preclude Orthotopic Bladder Substitution. J Urol. 2019; 201(5): 909–915.
    CrossRefPubMed
  161. Lebret T, Herve JM, Yonneau L, et al. After cystectomy, is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer? Eur Urol. 2002; 42(4): 344–9; discussion 349.
    CrossRefPubMed
  162. Madersbacher S, Studer UE. Contemporary cystectomy and urinary diversion. World J Urol. 2002; 20(3): 151–157.
    CrossRefPubMed
  163. Kouba EJ, Wallen EM, Pruthi RS. Gum chewing stimulates bowel motility in patients undergoing radical cystectomy with urinary diversion. Urology. 2007; 70(6): 1053–1056.
    CrossRefPubMed
  164. Karl A, Buchner A, Becker A, et al. A new concept for early recovery after surgery for patients undergoing radical cystectomy for bladder cancer: results of a prospective randomized study. J Urol. 2014; 191(2): 335–340.
    CrossRefPubMed
  165. Xu W, Daneshmand S, Bazargani ST, et al. Postoperative Pain Management after Radical Cystectomy: Comparing Traditional versus Enhanced Recovery Protocol Pathway. J Urol. 2015; 194(5): 1209–1213.
    CrossRefPubMed
  166. Lee C, Chang S, Kamat A, et al. Alvimopan Accelerates Gastrointestinal Recovery After Radical Cystectomy: A Multicenter Randomized Placebo-Controlled Trial. European Urology. 2014; 66(2): 265–272.
    CrossRef
  167. Chiang HA, Cheng PJ, Speed JM, et al. Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. Eur Urol Focus. 2020; 6(1): 74–80.
    CrossRefPubMed
  168. Brennan K, Karim S, Doiron RC, et al. Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study. Bladder Cancer. 2018; 4(4): 419–428.
    CrossRefPubMed
  169. Tikkinen K. EAU Guidelines Thromboprophylaxis in Urological Surgery. Edn presented at the 32th EAU Annual Congress London. EAU Guidelines Office, Arnhem 2017.
  170. Hautmann RE, Volkmer BG, Schumacher MC, et al. Long-term results of standard procedures in urology: the ileal neobladder. World J Urol. 2006; 24(3): 305–314.
    CrossRefPubMed
  171. Hautmann RE, de Petriconi RC, Volkmer BG. Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol. 2010; 184(3): 990–4; quiz 1235.
    CrossRefPubMed
  172. Stein JP, Ginsberg DA, Skinner DG. Indications and technique of the orthotopic neobladder in women. Urol Clin North Am. 2002; 29(3): 725–34, xi.
    CrossRef
  173. Hautmann RE, de Petriconi RC, Pfeiffer C, et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol. 2012; 61(5): 1039–1047.
    CrossRefPubMed
  174. Jentzmik F, Schrader AJ, de Petriconi R, et al. The ileal neobladder in female patients with bladder cancer: long-term clinical, functional, and oncological outcome. World J Urol. 2012; 30(6): 733–739.
    CrossRefPubMed
  175. Ahmadi H, Skinner EC, Simma-Chiang V, et al. Urinary functional outcome following radical cystoprostatectomy and ileal neobladder reconstruction in male patients. J Urol. 2013; 189(5): 1782–1788.
    CrossRef
  176. Neuzillet Y, Yonneau L, Lebret T, et al. The Z-shaped ileal neobladder after radical cystectomy: an 18 years experience with 329 patients. BJU Int. 2011; 108(4): 596–602.
    CrossRefPubMed
  177. Gershman B, Eisenberg MS, Thompson RH, et al. Comparative impact of continent and incontinent urinary diversion on long-term renal function after radical cystectomy in patients with preoperative chronic kidney disease 2 and chronic kidney disease 3a. Int J Urol. 2015; 22(7): 651–656.
    CrossRefPubMed
  178. Longo N, Imbimbo C, Fusco F, et al. Complications and quality of life in elderly patients with several comorbidities undergoing cutaneous ureterostomy with single stoma or ileal conduit after radical cystectomy. BJU Int. 2016; 118(4): 521–526.
    CrossRefPubMed
  179. Deliveliotis C, Papatsoris A, Chrisofos M, et al. Urinary diversion in high-risk elderly patients: modified cutaneous ureterostomy or ileal conduit? Urology. 2005; 66(2): 299–304.
    CrossRefPubMed
  180. Kilciler M, Bedir S, Erdemir F, et al. Comparison of ileal conduit and transureteroureterostomy with ureterocutaneostomy urinary diversion. Urol Int. 2006; 77(3): 245–250.
    CrossRefPubMed
  181. Figueroa AJ, Stein JP, Dickinson M, et al. Radical cystectomy for elderly patients with bladder carcinoma: an updated experience with 404 patients. Cancer. 1998; 83(1): 141–147, doi: 10.1002/(sici)1097-0142(19980701)83:1<141::aid-cncr19>3.0.co;2-x.
    PubMed
  182. Berger I, Wehrberger C, Ponholzer A, et al. Impact of the use of bowel for urinary diversion on perioperative complications and 90-day mortality in patients aged 75 years or older. Urol Int. 2015; 94(4): 394–400.
    CrossRefPubMed
  183. Nieuwenhuijzen JA, de Vries RR, Bex A, et al. Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions. Eur Urol. 2008; 53(4): 834–42; discussion 842.
    CrossRefPubMed
  184. Bricker EM, BRICKER EM. Bladder substitution after pelvic evisceration. Surg Clin North Am. 1950; 30(5): 1511–1521.
    CrossRefPubMed
  185. Mogg RA. The treatment of neurogenic urinary incontinence using the colonic conduit. Br J Urol. 1965; 37(6): 681–686.
    CrossRefPubMed
  186. Morales P, Golimbu M. Colonic urinary diversion: 10 years of experience. J Urol. 1975; 113(3): 302–307.
    CrossRefPubMed
  187. Wood DN, Allen SE, Hussain M, et al. Stomal complications of ileal conduits are significantly higher when formed in women with intractable urinary incontinence. J Urol. 2004; 172(6 Pt 1): 2300–2303.
    CrossRefPubMed
  188. Neal DE. Complications of ileal conduit diversion in adults with cancer followed up for at least five years. Br Med J (Clin Res Ed). 1985; 290(6483): 1695–1697.
    CrossRefPubMed
  189. Mues AC, Palacios JM, Haramis G, et al. Contemporary experience in the management of angiomyolipoma. J Endourol. 2010; 24(11): 1883–1886.
    CrossRefPubMed
  190. Donat SM, Siegrist T, Cronin A, et al. Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits? J Urol. 2010; 183(6): 2171–2177.
    CrossRefPubMed
  191. Hautmann RE, de Petriconi RC, Volkmer BG. 25 years of experience with 1,000 neobladders: long-term complications. J Urol. 2011; 185(6): 2207–2212.
    CrossRefPubMed
  192. Studer UE, Danuser H, Merz VW, et al. Experience in 100 patients with an ileal low pressure bladder substitute combined with an afferent tubular isoperistaltic segment. J Urol. 1995; 154(1): 49–56.
    PubMed
  193. Studer UE, Zingg EJ. Ileal orthotopic bladder substitutes. What we have learned from 12 years' experience with 200 patients. Urol Clin North Am. 1997; 24(4): 781–793.
    CrossRefPubMed
  194. Gburek BM, Lieber MM, Blute ML. Comparison of studer ileal neobladder and ileal conduit urinary diversion with respect to perioperative outcome and late complications. J Urol. 1998; 160(3 Pt 1): 721–723.
    CrossRefPubMed
  195. Parekh DJ, Gilbert WB, Koch MO, et al. Continent urinary reconstruction versus ileal conduit: a contemporary single-institution comparison of perioperative morbidity and mortality. Urology. 2000; 55(6): 852–855.
    CrossRefPubMed
  196. Granberg CF, Boorjian SA, Crispen PL, et al. Functional and oncological outcomes after orthotopic neobladder reconstruction in women. BJU Int. 2008; 102(11): 1551–1555.
    CrossRefPubMed
  197. Stein JP, Skinner DG. Surgical Atlas: The orthotopic T-pouch ileal neobladder. BJU Int. 2006; 98(2): 469–482.
    CrossRefPubMed
  198. Rapp DE, O'connor RC, Katz EE, et al. Neobladder-vaginal fistula after cystectomy and orthotopic neobladder construction. BJU Int. 2004; 94(7): 1092–5; discussion 1095.
    CrossRefPubMed
  199. Smith J, O'Connor R, Katz E, et al. Neobladder-Vaginal Fistula After Cystectomy and Orthotopic Neobladder Construction. J Urol. 2005; 174(3): 970–971.
    CrossRef
  200. Altobelli E, Buscarini M, Gill HS, et al. Complications of radical cystectomy. Minerva Urol Nefrol. 2007; 59(1): 67–87.
    PubMed
  201. Manoharan M, Ayyathurai R, Soloway MS. Radical cystectomy for urothelial carcinoma of the bladder: an analysis of perioperative and survival outcome. BJU Int. 2009; 104(9): 1227–1232.
    CrossRefPubMed
  202. Brendler CB, Steinberg GD, Marshall FF, et al. Local recurrence and survival following nerve-sparing radical cystoprostatectomy. J Urol. 1990; 144(5): 1137–40; discussion 1140.
    CrossRefPubMed
  203. Schoenberg MP, Walsh PC, Breazeale DR, et al. Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup. J Urol. 1996; 155(2): 490–494.
    PubMed
  204. Ong CHu, Schmitt M, Thalmann GN, et al. Individualized seminal vesicle sparing cystoprostatectomy combined with ileal orthotopic bladder substitution achieves good functional results. J Urol. 2010; 183(4): 1337–1341.
    CrossRefPubMed
  205. Mills RD, Studer UE. Metabolic consequences of continent urinary diversion. J Urol. 1999; 161(4): 1057–1066.
    PubMed
  206. Studer UE, Burkhard FC, Schumacher M, et al. Twenty years experience with an ileal orthotopic low pressure bladder substitute--lessons to be learned. J Urol. 2006; 176(1): 161–166.
    CrossRefPubMed
  207. Kassouf W, Hautmann RE, Bochner BH, et al. A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution? Eur Urol. 2010; 58(3): 374–383.
    CrossRefPubMed
  208. Sevin G, Koşar A, Perk H, et al. Bone mineral content and related biochemical variables in patients with ileal bladder substitution and colonic Indiana pouch. Eur Urol. 2002; 41(6): 655–659.
    CrossRefPubMed
  209. Gerharz EW, Månsson A, Hunt S, et al. Quality of life after cystectomy and urinary diversion: an evidence based analysis. J Urol. 2005; 174(5): 1729–1736.
    CrossRefPubMed
  210. Gerharz EW. Is there any evidence that one continent diversion is any better than any other or than ileal conduit? Curr Opin Urol. 2007; 17(6): 402–407.
    CrossRefPubMed
  211. Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol. 2005; 173(4): 1318–1322.
    CrossRefPubMed
  212. Mills RD, Fleischmann A, Studer UE. Radical cystectomy with an extended pelvic lymphadenectomy: rationale and results. Surg Oncol Clin N Am. 2007; 16(1): 233–245.
    CrossRefPubMed
  213. Buscarini M, Josephson DY, Stein JP. The evolving role of pelvic lymphadenectomy in the treatment of bladder cancer. Urol Oncol. 2004; 22(3): 205–11; discussion 212.
    CrossRefPubMed
  214. Schilling D, Horstmann M, Nagele U, et al. Cystectomy in women. BJU Int. 2008; 102(9 Pt B): 1289–1295.
    CrossRefPubMed
  215. Jensen JB, Ulhøi BP, Jensen KME. Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery. BJU Int. 2010; 106(2): 199–205.
    CrossRefPubMed
  216. Koppie TM, Vickers AJ, Vora K, et al. Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer. 2006; 107(10): 2368–2374.
    CrossRefPubMed
  217. Wright JL, Lin DW, Porter MP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer. 2008; 112(11): 2401–2408.
    CrossRefPubMed
  218. Wallmeroth A, Wagner U, Moch H, et al. Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): An autopsy study on 367 patients. Urol Int. 1999; 62(2): 69–75.
    CrossRefPubMed
  219. Davies JD, Simons CM, Ruhotina N, et al. Anatomic basis for lymph node counts as measure of lymph node dissection extent: a cadaveric study. Urology. 2013; 81(2): 358–363.
    CrossRefPubMed
  220. Zehnder P, Moltzahn F, Mitra AP, et al. Radical cystectomy with super-extended lymphadenectomy: impact of separate vs en bloc lymph node submission on analysis and outcomes. BJU Int. 2016; 117(2): 253–259.
    CrossRefPubMed
  221. Bruins HM, Veskimae E, Hernandez V, et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. Eur Urol. 2014; 66(6): 1065–1077.
    CrossRefPubMed
  222. Mandel P, Tilki D, Eslick GD. Extent of lymph node dissection and recurrence-free survival after radical cystectomy: a meta-analysis. Urol Oncol. 2014; 32(8): 1184–1190.
    CrossRefPubMed
  223. Bi L, Huang H, Fan X, et al. Extended vs non-extended pelvic lymph node dissection and their influence on recurrence-free survival in patients undergoing radical cystectomy for bladder cancer: a systematic review and meta-analysis of comparative studies. BJU Int. 2014; 113(5b): E39–E48.
    CrossRefPubMed
  224. Zehnder P, Studer UE, Skinner EC, et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol. 2011; 186(4): 1261–1268.
    CrossRefPubMed
  225. Simone G, Enein HA, Ferriero M, et al. 1755 EXTENDED VERSUS SUPER-EXTENDED PLND DURING RADICAL CYSTECTOMY: COMPARISON OF TWO PROSPECTIVE SERIES. Journal of Urology. 2012; 187(4S).
    CrossRef
  226. Gschwend JE, Heck M, Gschwend JE, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol. 2019; 75(4): 604–611.
    CrossRef
  227. Isaka S, Okano T, Sato N, et al. [Pelvic lymph node dissection for invasive bladder cancer]. Nihon Hinyokika Gakkai Zasshi. 1989; 80(3): 402–406.
    CrossRefPubMed
  228. Faraj K, Chang YHH, Neville MR, et al. Robotic vs. open cystectomy: How length-of-stay differences relate conditionally to age. Urologic Oncology: Seminars and Original Investigations. 2019; 37(6): 354.e1–354.e8.
    CrossRef
  229. Rai BP, Bondad J, Vasdev N, et al. Robotic versus open radical cystectomy for bladder cancer in adults. Cochrane Database Syst Rev. 2019; 4(4): CD011903.
    CrossRefPubMed
  230. Wilson TG, Guru K, Rosen RC, et al. Pasadena Consensus Panel. Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. European Urology. 2015; 67(3): 363–375.
    CrossRef
  231. Venkatramani V, Reis IM, Castle EP, et al. Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. Journal of Urology. 2020; 203(3): 522–529.
    CrossRef
  232. Hussein AA, May PR, Jing Z, et al. Collaborators. Outcomes of Intracorporeal Urinary Diversion after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. J Urol. 2018; 199(5): 1302–1311.
    CrossRefPubMed
  233. Zhang JjH, Ericson KJ, Thomas LJ, et al. Large Single Institution Comparison of Perioperative Outcomes and Complications of Open Radical Cystectomy, Intracorporeal Robot-Assisted Radical Cystectomy and Robotic Extracorporeal Approach. J Urol. 2020; 203(3): 512–521.
    CrossRefPubMed
  234. Tang K, Li H, Xia D, et al. Laparoscopic versus open radical cystectomy in bladder cancer: a systematic review and meta-analysis of comparative studies. PLoS One. 2014; 9(5): e95667.
    CrossRefPubMed
  235. Albisinni S, Rassweiler J, Abbou CC, et al. Long-term analysis of oncological outcomes after laparoscopic radical cystectomy in Europe: results from a multicentre study by the European Association of Urology (EAU) section of Uro-technology. BJU Int. 2015; 115(6): 937–945.
    CrossRefPubMed
  236. Khan MS, Gan C, Ahmed K, et al. A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL). Eur Urol. 2016; 69(4): 613–621.
    CrossRefPubMed
  237. Khan MS, Omar K, Ahmed K, et al. Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL). Eur Urol. 2020; 77(1): 110–118.
    CrossRefPubMed
  238. Steven K, Poulsen AL. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. J Urol. 2007; 178(4 Pt 1): 1218–23; discussion 1223.
    CrossRefPubMed
  239. Capitanio U, Suardi N, Shariat SF, et al. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int. 2009; 103(10): 1359–1362.
    CrossRefPubMed
  240. Sherif AHL, Rintala E, Mestad O, et al. Nordic Urothelial Cancer Group. Downstaging and pathoanatomical outcome following neoadjuvant cisplatinum based combination chemotherapy for muscle-invasive bladder carcinoma: An analysis of selected patients from two combined randomised prospective Nordic trials. Urology. 2006; 68(Suppl1): 137.
  241. Shen SS, Lerner SP, Muezzinoglu B, et al. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006; 37(6): 726–734.
    CrossRefPubMed
  242. Weizer AZ, Shah RB, Lee CT, et al. Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. Urol Oncol. 2007; 25(6): 460–464.
    CrossRefPubMed
  243. Freeman JA, Tarter TA, Esrig D, et al. Urethral recurrence in patients with orthotopic ileal neobladders. J Urol. 1996; 156(5): 1615–1619.
    PubMed
  244. Hardeman SW, Soloway MS. Urethral recurrence following radical cystectomy. J Urol. 1990; 144(3): 666–669.
    CrossRefPubMed
  245. Freeman JA, Esrig D, Stein JP, et al. Management of the patient with bladder cancer. Urethral recurrence. Urol Clin North Am. 1994; 21(4): 645–651.
    PubMed
  246. Stein JP, Clark P, Miranda G, et al. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol. 2005; 173(4): 1163–1168.
    CrossRefPubMed
  247. Huguet J, Palou J, Serrallach M, et al. Management of urethral recurrence in patients with Studer ileal neobladder. Eur Urol. 2003; 43(5): 495–498.
    CrossRefPubMed
  248. Varol C, Thalmann GN, Burkhard FC, et al. Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution. J Urol. 2004; 172(3): 937–942.
    CrossRefPubMed
  249. Mathers MJ, Zumbe J, Wyler S, et al. Is there evidence for a multidisciplinary follow-up after urological cancer? An evaluation of subsequent cancers. World J Urol. 2008; 26(3): 251–256.
    CrossRefPubMed
  250. Sanderson KM, Cai J, Miranda G, et al. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol. 2007; 177(6): 2088–2094.
    CrossRefPubMed
  251. Ok JH, Meyers FJ, Evans CP. Medical and surgical palliative care of patients with urological malignancies. J Urol. 2005; 174(4 Pt 1): 1177–1182.
    CrossRefPubMed
  252. Ubrig B, Lazica M, Waldner M, et al. Extraperitoneal bilateral cutaneous ureterostomy with midline stoma for palliation of pelvic cancer. Urology. 2004; 63(5): 973–975.
    CrossRefPubMed
  253. Zebic N, Weinknecht S, Kroepfl D. Radical cystectomy in patients aged > or = 75 years: an updated review of patients treated with curative and palliative intent. BJU Int. 2005; 95(9): 1211–1214.
    CrossRefPubMed
  254. El-Tabey NA, Osman Y, Mosbah A, et al. Bladder cancer with obstructive uremia: oncologic outcome after definitive surgical management. Urology. 2005; 66(3): 531–535.
    CrossRef
  255. Nagele U, Anastasiadis AG, Merseburger AS, et al. The rationale for radical cystectomy as primary therapy for T4 bladder cancer. World Journal of Urology. 2007; 25(4): 401–405.
    CrossRef
  256. Ghahestani SM, Shakhssalim N. Palliative treatment of intractable hematuria in context of advanced bladder cancer: a systematic review. Urol J. 2009; 6(3): 149–156.
    PubMed
  257. Srinivasan V, Brown CH, Turner AG. A comparison of two radiotherapy regimens for the treatment of symptoms from advanced bladder cancer. Clin Oncol (R Coll Radiol). 1994; 6(1): 11–13.
    CrossRefPubMed
  258. Horwich A, Babjuk M, Bellmunt J, et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Ann Oncol. 2019; 30(11): 1697–1727.
    CrossRef
  259. Witjes JA, Babjuk M, Bellmunt J, et al. Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]. Eur Urol. 2020; 78(1): e48–e50.
    CrossRef
  260. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. Eur Urol. 2021; 79(1): 62–79.
    CrossRef
  261. Janisch F, Shariat SF, Baltzer P, et al. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. World J Urol. 2020; 38(5): 1165–1175.
    CrossRefPubMed
  262. Cosentino M, Palou J, Gaya JM, et al. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol. 2013; 31(1): 141–145.
    CrossRefPubMed
  263. Messer J, et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011; 108: 701.
  264. Razavi SA, Sadigh G, Kelly AM, et al. Comparative effectiveness of imaging modalities for the diagnosis of upper and lower urinary tract malignancy: a critically appraised topic. Acad Radiol. 2012; 19(9): 1134–1140.
    CrossRefPubMed
  265. Rojas CP, Castle SM, Llanos CA, et al. Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma. Urol Oncol. 2013; 31(8): 1696–1700.
    CrossRefPubMed
  266. Seisen T, Peyronnet B, Dominguez-Escrig JL, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol. 2016; 70(6): 1052–1068.
    CrossRef
  267. Dominguez-Escrig JL, Peyronnet B, Seisen T, et al. Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. Eur Urol Focus. 2019; 5(2): 224–241.
    CrossRefPubMed
  268. Hwang EuC, Sathianathen NJ, Jung JH, et al. Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma. Cochrane Database Syst Rev. 2019; 5(5): CD013160.
    CrossRefPubMed
  269. Jeldres C, Lughezzani G, Sun M, et al. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol. 2010; 183(4): 1324–1329.
    CrossRefPubMed
  270. Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014; 32(34): 3801–3809.
    CrossRefPubMed
  271. Tunio MA, Hashmi A, Qayyum A, et al. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys. 2012; 82(3): e457–e462.
    CrossRefPubMed
  272. James N, Hussain S, Hall E, et al. Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer. N Engl J Med. 2012; 366(16): 1477–1488.
    CrossRef
  273. Nakamura R, Kakuhara H, Kikuchi K, et al. Partial Bladder Boost Using Lipiodol Marking During Image-guided Radiotherapy for Bladder Cancer. Anticancer Res. 2018; 38(8): 4827–4831.
    CrossRefPubMed
  274. Søndergaard J, Olsen KØ, Muren LP, et al. A study of image-guided radiotherapy of bladder cancer based on lipiodol injection in the bladder wall. Acta Oncol. 2010; 49(7): 1109–1115.
    CrossRefPubMed
  275. Shipley WU, Zietman AL, Kaufman DS, et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol. 2005; 15(1): 36–41.
    CrossRefPubMed
  276. Giacalone NJ, Shipley WU, Clayman RH, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017; 71(6): 952–960.
    CrossRefPubMed
  277. Kulkarni GS, Hermanns T, Wei Y, et al. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol. 2017; 35(20): 2299–2305.
    CrossRefPubMed
  278. Lin HY, Ye H, Kernen KM, et al. National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle-Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging. Cancer Med. 2018; 7(11): 5370–5381.
    CrossRefPubMed
  279. Christodoulou M, Reeves KJ, Hodgson C, et al. Outcomes of radiosensitisation in elderly patients with advanced bladder cancer. Radiother Oncol. 2018; 129(3): 499–506.
    CrossRefPubMed
  280. Wujanto C, Tey J, Chia D, et al. Radical radiotherapy in older patients with muscle invasive bladder cancer. J Geriatr Oncol. 2019; 10(2): 292–297.
    CrossRefPubMed
  281. Kijima T, Tanaka H, Koga F, et al. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients. BJU Int. 2019; 124(2): 242–250.
    CrossRefPubMed
  282. Coen JJ, Paly JJ, Niemierko A, et al. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2013; 86(2): 311–316.
    CrossRefPubMed
  283. Pietzak EJ, Sterling ME, Smith ZL, et al. Outcomes of radical cystectomy in potential candidates for bladder preservation therapy. Urology. 2015; 85(4): 869–875.
    CrossRefPubMed
  284. Efstathiou JA, Mouw KW, Gibb EA, et al. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. Eur Urol. 2019; 76(1): 59–68.
    CrossRefPubMed
  285. Sargos P, Baumann BC, Eapen L, et al. Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. Cancer Treat Rev. 2018; 70: 88–97.
    CrossRef
  286. Iwata T, Kimura S, Abufaraj M, et al. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. Urol Oncol. 2019; 37(10): 659–671.
    CrossRefPubMed
  287. Christodouleas JP, Baumann BC, He J, et al. Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer. 2014; 120(8): 1272–1280.
    CrossRefPubMed
  288. Zaghloul MS, Christodouleas JP, Smith A, et al. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial. JAMA Surg. 2018; 153(1): e174591.
    CrossRefPubMed
  289. Tey J, Ho F, Koh WY, et al. Palliative radiotherapy for bladder cancer: a systematic review and meta-analysis. Acta Oncol. 2021; 60(5): 635–644.
    CrossRefPubMed
  290. Duchesne G, Bolger JJ, Griffiths GO, et al. A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys. 2000; 47(2): 379–388.
    CrossRef
  291. Gakis G, Efstathiou J, Lerner SP, et al. International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013; 63(1): 45–57.
    CrossRefPubMed
  292. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23(21): 4602–4608.
    CrossRefPubMed
  293. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349(9): 859–866.
    CrossRefPubMed
  294. Bellmunt J, Hussain M, Gschwend JE, et al. IMvigor010 Study Group. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22(4): 525–537.
    CrossRefPubMed
  295. Sherif A, Rintala E, Mestad O, et al. Nordic Urothelial Cancer Group. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2. Scand J Urol Nephrol. 2002; 36(6): 419–425.
    CrossRefPubMed
  296. Sengeløv L, von der Maase H, Lundbeck F, et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol. 2002; 41(5): 447–456.
    CrossRefPubMed
  297. Martinez-Piñeiro JA, Gonzalez Martin M, Arocena F, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol. 1995; 153(3 Pt 2): 964–973.
    PubMed
  298. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003; 361(9373): 1927–1934.
    CrossRefPubMed
  299. Winquist E, Kirchner TS, Segal R, et al. Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004; 2 Pt 1: 561–559.
    CrossRefPubMed
  300. Yin M, Joshi M, Meijer RP, et al. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist. 2016; 21(6): 708–715.
    CrossRefPubMed
  301. Bamias A, Dafni U, Karadimou A, et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann Oncol. 2013; 24(4): 1011–1017.
    CrossRefPubMed
  302. Anari F, O'Neill J, Choi W, et al. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol. 2018; 1(1): 54–60.
    CrossRef
  303. Vetterlein MW, Wankowicz SAM, Seisen T, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer. 2017; 123(22): 4346–4355.
    CrossRefPubMed
  304. Matin SF, Margulis V, Kamat A, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010; 116(13): 3127–3134.
    CrossRefPubMed
  305. Liao RS, Gupta M, Schwen ZR, et al. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. J Urol. 2018; 200(1): 68–73.
    CrossRefPubMed
  306. Meng X, Chao B, Vijay V, et al. High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. Urology. 2019; 129: 146–152.
    CrossRefPubMed
  307. Kubota Y, Hatakeyama S, Tanaka T, et al. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget. 2017; 8(60): 101500–101508.
    CrossRefPubMed
  308. Hosogoe S, Hatakeyama S, Kusaka A, et al. Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma. Eur Urol Focus. 2018; 4(6): 946–953.
    CrossRefPubMed
  309. Porten S, Siefker-Radtke AO, Xiao L, et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014; 120(12): 1794–1799.
    CrossRefPubMed
  310. Margulis V, Puligandla M, Trabulsi EJ, et al. Collaborators. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2020; 203(4): 690–698.
    CrossRefPubMed
  311. National Cancer Institute: Common Terminology Criteria for Adverse Events wersja 5. https://ctep.cancer.gov/protocolDevelopment/electronic_ applications/ctc.html.
  312. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bladder Cancer Version 3.2021. https://www.nccn.org/professionals/ physician_gls/pdf/bladder.pdf (22.04.2021).
  313. Horwich A, Babjuk M, Bellmunt J, et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Ann Oncol. 2019; 30(11): 1697–1727.
    CrossRefPubMed
  314. Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015; 16(1): 76–86.
    CrossRefPubMed
  315. Bellmunt J, Orsola A, Leow JJ, et al. ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3: iii40–iii48.
    CrossRefPubMed
  316. eUpdate – Bladder Cancer Treatment Recommendations Published: 22 August 2019. Authors: ESMO Guidelines Committee.
  317. https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and- -metastatic/#7.
  318. Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020; 395(10232): 1268–1277.
    CrossRefPubMed
  319. Bellmunt J, Hussain M, Gschwend JE, et al. IMvigor010 Study Group. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22(4): 525–537.
    CrossRefPubMed
  320. Bianchi M, Roghmann F, Becker A, et al. Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. Can Urol Assoc J. 2014; 8(3-4): E148–E158.
    CrossRefPubMed
  321. Galsky MD, Krege S, Lin CC, et al. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urol Oncol. 2014; 32(1): 30.e15–30.e21.
    CrossRefPubMed
  322. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999; 17(10): 3173–3181.
    CrossRefPubMed
  323. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18(17): 3068–3077.
    CrossRefPubMed
  324. Sternberg CN, de Mulder P, Schornagel JH, et al. EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006; 42(1): 50–54.
    CrossRefPubMed
  325. Hussain SA, Stocken DD, Riley P, et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer. 2004; 91(5): 844–849.
    CrossRefPubMed
  326. Hussain SA, Palmer DH, Lloyd B, et al. A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett. 2012; 3(4): 855–859.
    CrossRefPubMed
  327. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012; 30(10): 1107–1113.
    CrossRefPubMed
  328. Alva A, Csoszi T, Ozguroglu M, et al. Pembrolizumab combined with chemotherapy vs chemotherapy alone as first-line therapy for advanced urothelial carcinoma: KEYNOTE-361. Presented at the European Society for Medical Oncology (ESMO) Virtual Congress, September 18–21, 2020.
  329. Galsky MD, Arija JÁ, Bamias A, et al. IMvigor130 Study Group. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020; 395(10236): 1547–1557.
    CrossRefPubMed
  330. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012; 30(2): 191–199.
    CrossRefPubMed
  331. Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012; 23(2): 406–410.
    CrossRefPubMed
  332. Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001; 19(12): 3018–3024.
    CrossRefPubMed
  333. Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997; 15(11): 3394–3398.
    CrossRefPubMed
  334. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017; 389(10064): 67–76.
    CrossRefPubMed
  335. Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017; 18(11): 1483–1492.
    CrossRefPubMed
  336. Powles T, Park S, Voog E, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020; 383(13): 1218–1230.
    CrossRefPubMed
  337. Meeks JJ, Taylor JM, Matsushita K, et al. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. BJU Int. 2013; 111(8): E325–E330.
    CrossRefPubMed
  338. Galsky MD, Iasonos A, Mironov S, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007; 69(2): 255–259.
    CrossRefPubMed
  339. Martin JW, Carballido EM, Ahmed A, et al. Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches. Arab J Urol. 2016; 14(3): 183–191.
    CrossRefPubMed
  340. Tatli AM, Uysal M, Goksu SS, et al. Complete response of primary bladder adenocarcinoma with the FOLFOX4 regimen. Urol Int. 2015; 94(3): 363–365.
    CrossRefPubMed
  341. Yanagihara Y, Tanji N, Miura N, et al. Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer. Chemotherapy. 2013; 59(6): 402–406.
    CrossRefPubMed
  342. Siefker-Radtke AO, Gee J, Shen Yu, et al. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. Journal Urol. 2003; 169(4): 1295–1298.
    CrossRefPubMed
  343. Choong NWW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 2005; 103(6): 1172–1178.
    CrossRefPubMed
  344. Pan Cx, Zhang H, Lara PN, et al. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Rev Anticancer Ther. 2006; 6(12): 1707–1713.
    CrossRefPubMed
  345. Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer. 1998; 34(8): 1208–1212.
    CrossRefPubMed
  346. Vaughn DJ, Broome CM, Hussain M, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 2002; 20(4): 937–940.
    CrossRefPubMed
  347. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997; 15(5): 1853–1857.
    CrossRefPubMed
  348. Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006; 24(21): 3451–3457.
    CrossRefPubMed
  349. Kanai K, Kikuchi E, Ohigashi T, et al. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Int J Clin Oncol. 2008; 13(6): 510–514.
    CrossRefPubMed
  350. Suyama T, Ueda T, Fukasawa S, et al. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol. 2009; 39(4): 244–250.
    CrossRefPubMed
  351. Fechner G, Siener R, Reimann M, et al. German Association Of Urologic Oncology (Auo) Bladder Cancer Study Group. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract. 2006; 60(1): 27–31.
    CrossRefPubMed
  352. Kouno T, Ando M, Yonemori K, et al. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol. 2007; 52(4): 1115–1122.
    CrossRefPubMed
  353. Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009; 27(27): 4454–4461.
    CrossRefPubMed
  354. Bellmunt J, Fougeray R, Rosenberg JE, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013; 24(6): 1466–1472.
    CrossRefPubMed
  355. Bellmunt J, de Wit R, Vaughn DJ, et al. KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017; 376(11): 1015–1026.
    CrossRefPubMed
  356. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021; 384(12): 1125–1135.
    CrossRefPubMed
  357. Bellmunt J, de Wit R, Fradet Y, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019; 30(6): 970–976.
    CrossRefPubMed
  358. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18(3): 312–322.
    CrossRefPubMed
  359. Powles T, O'Donnell PH, Massard C, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017; 3(9): e172411.
    CrossRefPubMed
  360. Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol. 2017; 28(12): 3044–3050.
    CrossRefPubMed
  361. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031): 1909–1920.
    CrossRefPubMed
  362. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018; 391(10122): 748–757.
    CrossRefPubMed
  363. McConkey DJ, Choi W, Ochoa A, et al. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol Oncol Clin North Am. 2015; 29(2): 377–94, x.
    CrossRefPubMed
  364. McConkey DJ, Choi W, Dinney CPN. Genetic subtypes of invasive bladder cancer. Curr Opin Urol. 2015; 25(5): 449–458.
    CrossRefPubMed
  365. Loriot Y, Necchi A, Park S, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019; 381(4): 338–348.
    CrossRef
  366. European Association of Urology (EAU), Oncology Guidelines [Internet]; Non-muscle-invasive Bladder Cancer, Publicated: 2020. http:// uroweb.org/guideline/non-muscle-invasive-bladder-cancer/ (04.2021).
  367. Palou J, Rodríguez-Rubio F, Millán F, et al. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. Urology. 2009; 73(6): 1313–1317.
    CrossRefPubMed
  368. Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol. 2002; 167(4): 1634–1637.
    PubMed
  369. European Association of Urology (EAU), Oncology Guidelines [Internet]; Muscle-invasive Bladder Cancer, Publicated: 2020. https:// uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/# 8 (04.2021).
  370. Gakis G, Black PC, Bochner BH, et al. Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. Eur Urol. 2017; 71(4): 545–557.
    CrossRefPubMed
  371. Picozzi S, Ricci C, Gaeta M, et al. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol. 2012; 188(6): 2046–2054.
    CrossRefPubMed
  372. Hautmann RE, Volkmer B, Egghart G, et al. Functional Outcome and Complications following Ileal Neobladder Reconstruction in Male Patients without Tumor Recurrence. More than 35 Years of Experience from a Single Center. J Urol. 2021; 205(1): 174–182.
    CrossRefPubMed
  373. Ploussard G, Xylinas E, Lotan Y, et al. Conditional survival after radical nephroureterectomy for upper tract carcinoma. Eur Urol. 2015; 67(4): 803–812.
    CrossRefPubMed
  374. Seisen T, Colin P, Rouprêt M. Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat Rev Urol. 2015; 12(3): 155–166.
    CrossRefPubMed
  375. European Association of Urology (EAU), Oncology Guidelines [Internet]; Upper Urinary Tract Urothelial Cell Carcinoma, Publicated: 2020. https://uroweb.org/guideline/upper-urinary-tract-urothelial-cell- -carcinoma (04.2021).
  376. Villa L, Cloutier J, Letendre J, et al. Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings. World J Urol. 2016; 34(9): 1201–1206.
    CrossRefPubMed
  377. Swartz MA, Porter MP, Lin DW, et al. Incidence of primary urethral carcinoma in the United States. Urology. 2006; 68(6): 1164–1168.
    CrossRefPubMed
  378. Krukowski J, Czajkowski M, Kłącz J, et al. Primary urethral carcinoma - unexpected cause of urethral stricture. Case report and review of the literature. Med Ultrason. 2019; 21(4): 494–496.
    CrossRefPubMed
  379. Sawczuk I, Acosta R, Grant D, et al. Squamous cell carcinoma. N Y State J Med. 1986; 86(5): 261–263.
    PubMed
  380. Arva NC, Das K. Diagnostic dilemmas of squamous differentiation in prostate carcinoma case report and review of the literature. Diagn Pathol. 2011; 6: 46.
    CrossRefPubMed
  381. Wiener JS, Liu ET, Walther PJ. Oncogenic human papillomavirus type 16 is associated with squamous cell cancer of the male urethra. Cancer Res. 1992; 52(18): 5018–5023.
    PubMed
  382. Guo H, Peng X, Jin C, et al. Lichen Sclerosus Accompanied by Urethral Squamous Cell Carcinoma: A Retrospective Study From a Urethral Referral Center. Am J Mens Health. 2018; 12(5): 1692–1699.
    CrossRefPubMed
  383. Thomas AA, Rackley RR, Lee U, et al. Urethral diverticula in 90 female patients: a study with emphasis on neoplastic alterations. J Urol. 2008; 180(6): 2463–2467.
    CrossRefPubMed
  384. Brierley JD, et al. TNM classification of malignant tumors. UICC International Union Against Cancer. 2017, Wiley/Blackwell. p. 208. https:// www.uicc.org/resources/tnm/publications-resources.
  385. EJ Eble J, SI, Sauter G, WHO Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs (IARC WHO Classification of Tumours). 2004, Lyon. https:// publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of- -Tumours/WHOClassification-Of-Tumours-Of-The-Urinary-System-And- Male-Genital-Organs-2016.
  386. Sui W, RoyChoudhury A, Wenske S, et al. Outcomes and Prognostic Factors of Primary Urethral Cancer. Urology. 2017; 100: 180–186.
    CrossRefPubMed
  387. Gheiler EL, Tefilli MV, Tiguert R, et al. Management of primary urethral cancer. Urology. 1998; 52(3): 487–493.
    CrossRefPubMed
  388. Karnes RJ, Breau RH, Lightner DJ. Surgery for urethral cancer. Urol Clin North Am. 2010; 37(3): 445–457.
    CrossRefPubMed
  389. Touijer AK, Dalbagni G. Role of voided urine cytology in diagnosing primary urethral carcinoma. Urology. 2004; 63(1): 33–35.
    CrossRefPubMed
  390. Gakis G, Efstathiou JA, Daneshmand S, et al. Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma. Urol Int. 2016; 97(2): 134–141.
    CrossRefPubMed
  391. Del Gaizo A, Silva AC, Lam-Himlin DM, et al. Magnetic resonance imaging of solid urethral and peri-urethral lesions. Insights Imaging. 2013; 4(4): 461–469.
    CrossRefPubMed
  392. Dayyani F, Pettaway CA, Kamat AM, et al. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol. 2013; 31(7): 1171–1177.
    CrossRefPubMed
  393. RARECARENet. Surveillance of Rare Cancers in Europe. https:// www.rarecancerseurope.org/About-Rare-Cancers/families-and-list- -of-rare-cancers.
  394. Rabbani F. Prognostic factors in male urethral cancer. Cancer. 2011; 117(11): 2426–2434.
    CrossRefPubMed
  395. Dalbagni G, Zhang ZF, Lacombe L, et al. Male urethral carcinoma: analysis of treatment outcome. Urology. 1999; 53(6): 1126–1132.
    CrossRefPubMed
  396. Dimarco DS, Dimarco CS, Zincke H, et al. Surgical treatment for local control of female urethral carcinoma. Urol Oncol. 2004; 22(5): 404–409.
    CrossRefPubMed
  397. Garden A, Zagars G, Delclos L. Primary carcinoma of the female urethra results of radiation therapy. Cancer. 1993; 71(10): 3102–3108, doi: 10.1002/1097-0142(19930515)71:10<3102::aid-cncr2820711034>3.0.co;2-2.
    PubMed
  398. Zinman L, Vanni A. Management of Proximal Primary Urethral Cancer. Urol Clin North Am. 2016; 43(4): 505–513.
    CrossRefPubMed
  399. Kent M, Zinman L, Girshovich L, et al. Combined chemoradiation as primary treatment for invasive male urethral cancer. J Urol. 2015; 193(2): 532–537.
    CrossRefPubMed
  400. Gakis G, Morgan T, Daneshmand S, et al. Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer. Journal of Clinical Oncology. 2015; 33(15_suppl): 4568–4568.
    CrossRef
  401. Gofrit ON, Pode D, Pizov G, et al. Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy? BJU Int. 2009; 103(7): 905–908.
    CrossRefPubMed
  402. Vazina A, Dugi D, Shariat SF, et al. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol. 2004; 171(5): 1830–1834.
    CrossRefPubMed
  403. Shukla CJ, Shabbir M, Feneley MR, et al. Palliation of male genital cancers. Clin Oncol (R Coll Radiol). 2010; 22(9): 747–754.
    CrossRefPubMed

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl